Myeloproliferative Neoplasm

Treatment with hydroxycarbamide and ruxolitinib resulted in decreased platelet counts and improved vasculitis, with no subsequent recurrence of cardiovascular events. This rare case shows that ruxolitinib can be effective in treating vasculitis complications in patients with JAK2 mutation-positive ET.

These findings highlight the need for enhanced understanding of MDS pathogenesis across patient groups and refined prognostic tools to improve personalized management of MDS spectrum conditions. Trial Registration: ClinicalTrials.gov identifier: NCT02775383.

The patient received cytoreductive therapy with hydroxycarbamide, combined with dual antiplatelet therapy...Recently, JAK2 V617F mutation in vascular endothelial cells of patients with MPN has been documented, suggesting a potential association between MPN and arterial dissection or dissecting aneurysm. Although rare, such vascular complications can be life-threatening and should be recognized as clinically significant.

Although thrombosis prevention is crucial in ET, anagrelide is associated with a higher risk of bleeding events than other therapies. To our knowledge, this is the first reported case of gastric intramural hematoma associated with ET and anagrelide.

P1, N=100, Recruiting, Prelude Therapeutics | Not yet recruiting --> Recruiting

P2, N=121, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Apr 2027 --> Jan 2026 | Trial primary completion date: Apr 2027 --> Jan 2026

P=N/A, N=200, Recruiting, iOMEDICO AG | Not yet recruiting --> Recruiting

P2, N=30, Recruiting, University of Southern California | Trial primary completion date: Mar 2026 --> Dec 2026

This study highlights a case of MPN with a more clinically aggressive Type 1 calreticulin (CALR) mutation, where a combination of low-dose IL-2 immunotherapy and targeted therapy with oral tretinoin (all-trans retinoic acid, ATRA, a vitamin A derivative) improved immune cells, particularly NK-cell-mediated destruction of malignant cells, reduced CALR mutation levels to undetectable, and alleviated disease symptoms. The aim is to offer a new, low-toxicity personalized treatment strategy that eradicates cancer-initiating stem cells, reduces side effects, and provides an option for patients with limited conventional therapy alternatives.

BRAF mutations in myeloid neoplasms are rare, heterogeneous, and usually represent secondary events in clonal evolution. Although mutation clearance appears prognostically relevant, current targeted approaches provide limited durability, underscoring the need for prospective studies in this setting.

The rare e1a2 BCR::ABL1 transcript was notably prevalent which is associated with TKI resistance and a more aggressive disease course in CML. We described superior survival in those with Ph-negative MPN preceding CML, with median OS not reached, compared with 277 months for CML preceding Ph-negative MPN and 100 months for those diagnosed simultaneously (p = 0.05).

A literature review of all children with PDGFRB rearrangement was collated in our analysis. The challenges of diagnosis, treatment, and follow-up posed by such a rare genetic disorder with no pediatric guidelines are being discussed.